Next Phase Newsletter

A French venture capital firm that has an additional office in the USA is actively seeking investment opportunities within life sciences and healthcare sectors, with a focus on early stage. Initial investments can range from $100K – 3M, and largely varies by deal. The firm typically invests in the form of equity, and may take less equity in exchange for preemptive or pro-rata rights. The firm will consider global opportunities but focuses on USA and Europe-based companies. 

The firm is interested in various opportunities within therapeutics, devices, diagnostics, and digital health. In therapeutics, the firm is excited about platform technologies (especially in oncology), DNA repair, and novel drug delivery mechanisms. Within devices, technologies that integrate or combine new technologies such as robotics, smart devices, IoT, and imaging are areas of interest. In diagnostics, point of care diagnostics technologies that can substantially transform the current standard of care are of interest. Lastly, within digital health, the firm is interested in telehealth, novel digital interventions, and any technology that successfully leverages AI to improve patient outcomes and clinical workflow. The firm is mostly stage and indication agnostic but tend to stray away from cardiovascular and CNS indications. 

The firm has no specific company or management team requirements. The firm seeks to be a very active, hands-on investor and can support their portfolio companies on their operations, scalability, regulatory strategy, and more. The firm has a growing advisory board that companies can seek to leverage. The firm can act as either a lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A premier Saudi investment firm boasts a diverse portfolio that spans multiple asset classes, including real assets and alternative investments. Over the past decade, the investment firm has evolved into one of the region’s most compelling success stories, driven by a steadfast commitment to delivering value, fostering partnerships, and catalyzing sustainable development. Their vision is to become a leading integrated solutions provider in cell and gene therapy in Saudi Arabia, establishing themselves as the first globally trusted partner in precision medicine within the Middle East. The firm focus on providing research, manufacturing, and a comprehensive range of services related to genomic medicine, targeting local, regional, and international markets. Check sizes vary and are flexible but on average range between USD $5-10M. The firm aims to act as a catalyst for developing this vital industry and emphasize the importance of the private sector in supporting emerging, innovative sectors. Their aspiration is to accelerate the delivery of groundbreaking innovations and ensure patient access to treatments for chronic and rare diseases in the region. The firm is committed to contributing to the localization of the biotechnology industry as part of the global system and building national expertise to achieve these ambitious goals. 

Within therapeutics, the firm is focused on cell and gene therapy in IND, Phase 1 and/or moving into Phase 2. There are several indications of interest, including orphan diseases, oncology, neurology, immunology, cardiovascular diseases, and diabetes. For Tech-Driven Biosciences, the firm is interested in AI-driven platforms for drug discovery and clinical development. 

The firm is only interested in companies willing to work with Saudi Arabia toward the goal of bringing biotech innovation to the region through manufacturing and clinical development. A carve out or partnership in the region is necessary. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm that manages just under $100 million in assets across 4 funds makes equity investments into companies ranging from a few hundred thousand dollars to $3 million with additional capital reserved for follow on rounds. The firm is looking for companies located throughout the United States and plans to make 2-3 new investments over the next 9-12 months. The firm will invest in both seed and later stage companies. 

The firm is looking for companies developing Medical Devices and Diagnostics, Healthcare IT products and Life Science Research Tools with an emphasis on fast to market low capital intense products that reduce the cost of delivering quality healthcare. The firm is open to all sub-sectors and indications in the medical technology space except for those targeting diseases and disorders of the spine. 

The firm is looking for companies with skilled and experienced management teams. The firm generally looks to take a board seat into companies after investment and play an active role in the management. The firm is willing to invest in both public and privately held companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A VC firm is investing from its fifth fund that was closed in 2023. The firm focuses exclusively on early stage and seed investments in medical device companies. The firm provides seed, first, or second round of financing, typically in equity. The initial investment in a company ranges from $250K to $3M, with follow-on financing rounds. Accordingly, the firm invests between $2-6M over the life of an investment. The firm typically invests in companies that are based in the US, but may consider exceptional opportunities abroad. The firm is actively seeking new investment opportunities. 

The firm is specifically looking for medical devices that address cardiovascular, orthopedic indications. The firm has no clinical requirements and will invest in design stage. The product must be based on strongly protected IP. 

The firm prefers to invest in companies that are not looking to develop their own sales team, but rather developing a technology that can be sold at a healthy premium to a company which already has the requisite sales and marketing teams in place. The firm generally takes a board seat, but is not a requirement. In addition, the firm prefers to assume a role on the company’s scientific advisory board. The firm is looking for companies with a strong and experienced management team. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A global investment firm focuses on private venture and growth assets. The firm manages over USD 2 billion and invests in highly innovative and disruptive companies in the biotechnology, enterprise-facing core technology, and consumer sectors. The firm is open to global companies in Pre-Seed to Series B rounds and prefers to lead its investments. The firm is capable of investing up to $25M USD. 
 
Within life sciences, the firm invests in therapeutics and med-techs with strong preference in aging-related indications including, but not limited to, oncology, immunology, neurology, ophthalmology, cardiovascular, liver, and kidney diseases. The firm typically avoids rare diseases as the firm emphasizes breakthrough technologies. The firm is open to company being as early as discovery stages. 
 
The firm prefers to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A venture capital firm based in the US actively invests and provides support to companies interested in China market entry, but companies do not need to have a China angle. The firm has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. Since its establishment, the firm has invested in over 60 companies and continues to actively seek life science investments with its third fund, aiming to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies based in USA and China. 
 
The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment. 
 
The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A boutique venture capital firm with offices in US and the Middle East has invested alongside Tier 1 VCs in several companies with 5 exits qualified as unicorns. The firm is stage-agnostic and can invest at any stage. With this said, check sizes are flexible and can range from $500K – $15M. Their capital comes mostly from qualified purchasers (investors) located in the MENA region at large and GCC region specifically. To date, the firm has invested in USA based companies. 
 
The firm is focused on healthcare, energy, ICT and infotech and most recently data defined networks addressing the systems aging and longevity (and research at large) pain points. The firm has invested in medi-tech, health-tech and biotech in the past which includes but not limited to diagnostics, medical devices, therapeutics, and digital health. The firm invests within 4 pillars of longevity roadmap covering health span and lifespan namely: (a) preventative, (b) replacement, (c) biostasis, and (d) therapeutics and genetic engineering on the basis that they are targeting systems aging and longevity.  

 
The firm prefers a management team with domain expertise, past performance and PhD’s / higher educational pedigree. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.